Loading…

High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells

The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the...

Full description

Saved in:
Bibliographic Details
Published in:BMC biotechnology 2013-06, Vol.13 (1), p.52-52, Article 52
Main Authors: Jäger, Volker, Büssow, Konrad, Wagner, Andreas, Weber, Susanne, Hust, Michael, Frenzel, André, Schirrmann, Thomas
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3
cites cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3
container_end_page 52
container_issue 1
container_start_page 52
container_title BMC biotechnology
container_volume 13
creator Jäger, Volker
Büssow, Konrad
Wagner, Andreas
Weber, Susanne
Hust, Michael
Frenzel, André
Schirrmann, Thomas
description The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility. In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average. Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.
doi_str_mv 10.1186/1472-6750-13-52
format article
fullrecord <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3699382</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A534630796</galeid><sourcerecordid>A534630796</sourcerecordid><originalsourceid>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</originalsourceid><addsrcrecordid>eNqNkt9rFDEQxxdRbK0--yYLvujDtvm1yeZFKKV6RwsVf72GJDu5puwlZ7Jb7H9vlrZnTwRLCJlkPvNNMjNV9RqjQ4w7foSZIA0XLWowbVrypNrfnjx9YO9VL3K-QgiLDvHn1R6hHSIdw_uVW_jVZT3ANQz1mHTIHsJYb1LsJzv6GOro6gQ2ro0PunjK9Cb2HnIx-_vtTe2mPNMlcAQfcu1DvTg9I5LWFoYhv6yeOT1keHW3HlTfP55-O1k05xeflifH543lhI6NdUbq3oEQsnNMYo64JYw5xIVtO8qlFgYZJ7nuGaLIUWMMBcmJcQgEMfSg-nCru5nMGnpbPpP0oDbJr3W6UVF7tesJ_lKt4rUq2pJ2pAi8uxNI8ecEeVRrn-cv6ABxygq3rOO03Cj-jzJM2pYw0hb07V_oVZxSKJlQmMqOMsQI_kOt9ADKBxfLE-0sqo5byjhFQvJCHf6DKqOHtbcxgPPlfCfg_U5AYUb4Na70lLM6-7x8NLv8-uXx7MWPXfbolrUp5pzAbUuCkZo7Wc29quZeLRlR7VyINw8rueXvW5f-Bnxi6nc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1398340421</pqid></control><display><type>article</type><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</creator><creatorcontrib>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</creatorcontrib><description>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility. In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average. Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</description><identifier>ISSN: 1472-6750</identifier><identifier>EISSN: 1472-6750</identifier><identifier>DOI: 10.1186/1472-6750-13-52</identifier><identifier>PMID: 23802841</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Antigens ; Cloning ; Cloning, Molecular ; Construction contracts ; Deoxyribonucleic acid ; DNA ; Epstein-Barr virus ; Genes ; Genetic Vectors ; HEK293 Cells ; Humans ; Immunoglobulin Fc Fragments - biosynthesis ; Microbiology ; Monoclonal antibodies ; Peptide Library ; Proteins ; Recombinant Fusion Proteins - biosynthesis ; Recombinant proteins ; Ribonucleases - biosynthesis ; Single-Chain Antibodies - biosynthesis</subject><ispartof>BMC biotechnology, 2013-06, Vol.13 (1), p.52-52, Article 52</ispartof><rights>COPYRIGHT 2013 BioMed Central Ltd.</rights><rights>2013 Jäger et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</rights><rights>Copyright © 2013 Jäger et al.; licensee BioMed Central Ltd. 2013 Jäger et al.; licensee BioMed Central Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</citedby><cites>FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3699382/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/1398340421?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23802841$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jäger, Volker</creatorcontrib><creatorcontrib>Büssow, Konrad</creatorcontrib><creatorcontrib>Wagner, Andreas</creatorcontrib><creatorcontrib>Weber, Susanne</creatorcontrib><creatorcontrib>Hust, Michael</creatorcontrib><creatorcontrib>Frenzel, André</creatorcontrib><creatorcontrib>Schirrmann, Thomas</creatorcontrib><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><title>BMC biotechnology</title><addtitle>BMC Biotechnol</addtitle><description>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility. In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average. Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</description><subject>Antigens</subject><subject>Cloning</subject><subject>Cloning, Molecular</subject><subject>Construction contracts</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>Epstein-Barr virus</subject><subject>Genes</subject><subject>Genetic Vectors</subject><subject>HEK293 Cells</subject><subject>Humans</subject><subject>Immunoglobulin Fc Fragments - biosynthesis</subject><subject>Microbiology</subject><subject>Monoclonal antibodies</subject><subject>Peptide Library</subject><subject>Proteins</subject><subject>Recombinant Fusion Proteins - biosynthesis</subject><subject>Recombinant proteins</subject><subject>Ribonucleases - biosynthesis</subject><subject>Single-Chain Antibodies - biosynthesis</subject><issn>1472-6750</issn><issn>1472-6750</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNqNkt9rFDEQxxdRbK0--yYLvujDtvm1yeZFKKV6RwsVf72GJDu5puwlZ7Jb7H9vlrZnTwRLCJlkPvNNMjNV9RqjQ4w7foSZIA0XLWowbVrypNrfnjx9YO9VL3K-QgiLDvHn1R6hHSIdw_uVW_jVZT3ANQz1mHTIHsJYb1LsJzv6GOro6gQ2ro0PunjK9Cb2HnIx-_vtTe2mPNMlcAQfcu1DvTg9I5LWFoYhv6yeOT1keHW3HlTfP55-O1k05xeflifH543lhI6NdUbq3oEQsnNMYo64JYw5xIVtO8qlFgYZJ7nuGaLIUWMMBcmJcQgEMfSg-nCru5nMGnpbPpP0oDbJr3W6UVF7tesJ_lKt4rUq2pJ2pAi8uxNI8ecEeVRrn-cv6ABxygq3rOO03Cj-jzJM2pYw0hb07V_oVZxSKJlQmMqOMsQI_kOt9ADKBxfLE-0sqo5byjhFQvJCHf6DKqOHtbcxgPPlfCfg_U5AYUb4Na70lLM6-7x8NLv8-uXx7MWPXfbolrUp5pzAbUuCkZo7Wc29quZeLRlR7VyINw8rueXvW5f-Bnxi6nc</recordid><startdate>20130626</startdate><enddate>20130626</enddate><creator>Jäger, Volker</creator><creator>Büssow, Konrad</creator><creator>Wagner, Andreas</creator><creator>Weber, Susanne</creator><creator>Hust, Michael</creator><creator>Frenzel, André</creator><creator>Schirrmann, Thomas</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>KPI</scope><scope>3V.</scope><scope>7QO</scope><scope>7TB</scope><scope>7U5</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>L7M</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20130626</creationdate><title>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</title><author>Jäger, Volker ; Büssow, Konrad ; Wagner, Andreas ; Weber, Susanne ; Hust, Michael ; Frenzel, André ; Schirrmann, Thomas</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Antigens</topic><topic>Cloning</topic><topic>Cloning, Molecular</topic><topic>Construction contracts</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>Epstein-Barr virus</topic><topic>Genes</topic><topic>Genetic Vectors</topic><topic>HEK293 Cells</topic><topic>Humans</topic><topic>Immunoglobulin Fc Fragments - biosynthesis</topic><topic>Microbiology</topic><topic>Monoclonal antibodies</topic><topic>Peptide Library</topic><topic>Proteins</topic><topic>Recombinant Fusion Proteins - biosynthesis</topic><topic>Recombinant proteins</topic><topic>Ribonucleases - biosynthesis</topic><topic>Single-Chain Antibodies - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jäger, Volker</creatorcontrib><creatorcontrib>Büssow, Konrad</creatorcontrib><creatorcontrib>Wagner, Andreas</creatorcontrib><creatorcontrib>Weber, Susanne</creatorcontrib><creatorcontrib>Hust, Michael</creatorcontrib><creatorcontrib>Frenzel, André</creatorcontrib><creatorcontrib>Schirrmann, Thomas</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>Gale In Context: Global Issues</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Mechanical &amp; Transportation Engineering Abstracts</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Health &amp; Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Advanced Technologies Database with Aerospace</collection><collection>ProQuest Biological Science Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC biotechnology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jäger, Volker</au><au>Büssow, Konrad</au><au>Wagner, Andreas</au><au>Weber, Susanne</au><au>Hust, Michael</au><au>Frenzel, André</au><au>Schirrmann, Thomas</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells</atitle><jtitle>BMC biotechnology</jtitle><addtitle>BMC Biotechnol</addtitle><date>2013-06-26</date><risdate>2013</risdate><volume>13</volume><issue>1</issue><spage>52</spage><epage>52</epage><pages>52-52</pages><artnum>52</artnum><issn>1472-6750</issn><eissn>1472-6750</eissn><abstract>The demand of monospecific high affinity binding reagents, particularly monoclonal antibodies, has been steadily increasing over the last years. Enhanced throughput of antibody generation has been addressed by optimizing in vitro selection using phage display which moved the major bottleneck to the production and purification of recombinant antibodies in an end-user friendly format. Single chain (sc)Fv antibody fragments require additional tags for detection and are not as suitable as immunoglobulins (Ig)G in many immunoassays. In contrast, the bivalent scFv-Fc antibody format shares many properties with IgG and has a very high application compatibility. In this study transient expression of scFv-Fc antibodies in human embryonic kidney (HEK) 293 cells was optimized. Production levels of 10-20 mg/L scFv-Fc antibody were achieved in adherent HEK293T cells. Employment of HEK293-6E suspension cells expressing a truncated variant of the Epstein Barr virus (EBV) nuclear antigen (EBNA) 1 in combination with production under serum free conditions increased the volumetric yield up to 10-fold to more than 140 mg/L scFv-Fc antibody. After vector optimization and process optimization the yield of an scFv-Fc antibody and a cytotoxic antibody-RNase fusion protein further increased 3-4-fold to more than 450 mg/L. Finally, an entirely new mammalian expression vector was constructed for single step in frame cloning of scFv genes from antibody phage display libraries. Transient expression of more than 20 different scFv-Fc antibodies resulted in volumetric yields of up to 600 mg/L and 400 mg/L in average. Transient production of recombinant scFv-Fc antibodies in HEK293-6E in combination with optimized vectors and fed batch shake flasks cultivation is efficient and robust, and integrates well into a high-throughput recombinant antibody generation pipeline.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>23802841</pmid><doi>10.1186/1472-6750-13-52</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1472-6750
ispartof BMC biotechnology, 2013-06, Vol.13 (1), p.52-52, Article 52
issn 1472-6750
1472-6750
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3699382
source Publicly Available Content Database; PubMed Central
subjects Antigens
Cloning
Cloning, Molecular
Construction contracts
Deoxyribonucleic acid
DNA
Epstein-Barr virus
Genes
Genetic Vectors
HEK293 Cells
Humans
Immunoglobulin Fc Fragments - biosynthesis
Microbiology
Monoclonal antibodies
Peptide Library
Proteins
Recombinant Fusion Proteins - biosynthesis
Recombinant proteins
Ribonucleases - biosynthesis
Single-Chain Antibodies - biosynthesis
title High level transient production of recombinant antibodies and antibody fusion proteins in HEK293 cells
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T02%3A05%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=High%20level%20transient%20production%20of%20recombinant%20antibodies%20and%20antibody%20fusion%20proteins%20in%20HEK293%20cells&rft.jtitle=BMC%20biotechnology&rft.au=J%C3%A4ger,%20Volker&rft.date=2013-06-26&rft.volume=13&rft.issue=1&rft.spage=52&rft.epage=52&rft.pages=52-52&rft.artnum=52&rft.issn=1472-6750&rft.eissn=1472-6750&rft_id=info:doi/10.1186/1472-6750-13-52&rft_dat=%3Cgale_pubme%3EA534630796%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c623t-cfb9adfe7798f491606c244f067c58369a7b0bf96ad4030f3bbb3e962bf0e72b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1398340421&rft_id=info:pmid/23802841&rft_galeid=A534630796&rfr_iscdi=true